$TRAW News

Traws Pharma Enters Stock Purchase Agreement With Roth Principal Investments On Oct 23, 2026; May Sell Up To $50M In Common Stock To Roth Principal Investments

HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target

Traws Pharma shares rise after Q2 loss comes in better than expected

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate

Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2M

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Traws Pharma Announces That An Updated Toxicology Data Package Is Being Developed In Response To The UK MHRA's Information Requirements For Planned Testing Of Tivoxavir Marboxil In A Phase 2a Human Influenza Challenge Study

HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price Target

Ladenburg Thalmann Downgrades Traws Pharma to Neutral

Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study

Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study

Why Did TRAW Stock Slump 28% After Hours?

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma Defers Planned Phase 2a Influenza Study Of Tivoxavir Marboxil After Negative UK MHRA Review; Cash Runway Extends To Q1 2027; Advancing Alternative Influenza Antiviral Candidates

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Traws Pharma Announces Advancement Of Its Novel Proprietary Broad-Spectrum Combination Anti-Viral Agent With Potential Utility Against Hantavirus, Ebola and Lassa

HC Wainwright & Co. Reiterates Buy on Traws Pharma, Maintains $8 Price Target

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate